We are an immuno-oncology company advancing a pipeline of next generation, transformative cancer treatments.

DC Investment Partners

HBM Healthcare Investments AG

Adage Capital Management

RA Capital Management

Longwood Fund

MPM Capital

Soleus Capital

Sphera Global Healthcare Fund

Taiho Ventures

UPMC Enterprises

Werewolf Therapeutics

We are excited to share preliminary monotherapy data from our WTX-124 Phase 1/1b clinical trial at Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting. https://bit.ly/45SOV8Y #ImmunoOncology #Cytokines #SITC2023 #HOWL

Excited to be at SITC in San Diego to present 6 posters sharing Wereowlf’s exciting advancement and data!

We’re #hiring a new Accountant in Watertown, Massachusetts. Apply today or share this post with your network.

Werewolf will be @ SITC and would welcome discussions with investors and partners. Reach out to me! See you in San Diego.

We are looking forward to the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting. Be sure to visit our six poster presentations, including interim first-in-human clinical data from our WTX-124 Phase 1/1b study. Learn More: https://lnkd.in/gjjR58w3
#ImmunoOncology #Cytokines #SITC2023 $HOWL

On Sunday 9/24 we are honored to recognize #WorldCancerResearchDay and raise awareness for #cancerresearch. At Werewolf we remain committed to transforming cancer treatment through innovation. Learn more here https://werewolftx.com/

Moonlight Therapeutics is a biopharmaceutical company specializing in innovative immuno-oncology therapeutics.

Moonlight Therapeutics

Nightshade Biotech is a healthcare company focused on developing cutting-edge immuno-oncology treatments and therapies.

Nightshade Biotech

Werewolf Therapeutics, Inc. is a biopharmaceutical company focused on developing therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company's proprietary PREDATOR platform designs conditionally activated molecules that stimulate adaptive and innate immunity to address the limitations of conventional proinflammatory immune therapies.

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. The company is also developing WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Werewolf Therapeutics, Inc.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general	Mar 8, 2024 9:13 AM	1edc21b2
public peers	general
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general	Mar 8, 2024 9:13 AM	c6cd33db
company summary	general
signals	general	Mar 8, 2024 9:13 AM	a0ed6554
crunchbase trigger	general
crunchbase profile	general
li profile	general	Mar 8, 2024 9:13 AM	9461e28b
translate crunchbase fundingrounds	general
peers	general	Mar 8, 2024 9:13 AM	3b182ce4
news basic	general	Mar 8, 2024 9:13 AM	22d669c5
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:WEREWOLFTX

Werewolf Therapeutics, Inc.

Last Close

1.64

21/11 21:00

Market Cap

95.60M

Beta: -

Volume Today

564.68K

Avg: -